Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from JJ.

“Impressive value for guitarists seeking rich clean/overdrive tones and timeless distortion tones”: PRS Archon Classic Head review

The PRS Archon Classic runs the gamut from crystal cleans to classic crunch and hot-rodded high gain

2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025

2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025

These blue-chip stocks offer a rare combination of stability, resilience, and moderate growth.

Stock Of The Day: Breakout In Johnson & Johnson

Stock Of The Day: Breakout In Johnson & Johnson

Johnson Johnson (NYSE:JNJ) stalled out at resistance around the $165 level. There tends to be resistance at price levels that had previously been resistance. As you can see on the chart below, that's the case here. This level was also resistance in March.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Dow's J&J Surges; Why Its Report Is Also Bullish For Stryker, Medtronic, Boston Scientific

Johnson & Johnson stock jumped Wednesday after the Dow health behemoth raised its guidance in the wake of a bullish second-quarter report.

Investors Business Daily

Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors

The company will likely focus on off-loading smaller beauty brands.

6 Stocks to Buy to Give Your Portfolio the Perfect Mix of Growth, Value, and Defense

This blend of stocks may be the key to long-term success.

Build a Bulletproof Dividend Portfolio With These 5 Defensive Stocks

These defensive stocks pay reliable dividends.

inkl

Read news from The Economist, FT, and more,
with one subscription

2 Companies Now Have Credit Ratings Higher Than The U.S.

2 Companies Now Have Credit Ratings Higher Than The U.S.

The U.S. may have just lost its AAA rating — but at least there are still financially responsible U.S. companies left.

Investors Business Daily

Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News

Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News

Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use additive products.

Investors Business Daily

J&J Snack Foods Hits New 52-Week Low: Time to Buy?

J&J Snack Foods Hits New 52-Week Low: Time to Buy?

Among the 96 Nasdaq stocks hitting new 52-week lows Tuesday was the New Jersey-based manufacturer of snack foods and frozen beverages. The small-cap stock hit its 10th new 52-week low over the past 12 months. Time to buy?

CG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer Drug

CG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer Drug

Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer treatment.

Investors Business Daily

UnitedHealth spent $1.7 million on executive security last year, 4 times the corporate average. Experts expect the figure to keep climbing

UnitedHealth spent $1.7 million on executive security last year, 4 times the corporate average. Experts expect the figure to keep climbing

UnitedHealth Group reported its executive security compensation months after the CEO of health insurance arm UnitedHealthcare was fatally shot in December.

Stock Market Tumbles On Nvidia Export Curbs, Fed Chief Powell, UnitedHealth: Weekly Review

Stock Market Tumbles On Nvidia Export Curbs, Fed Chief Powell, UnitedHealth: Weekly Review

The stock market sold off this week, with Nvidia AI chip export curbs, UnitedHealth guidance and Fed chief Jerome Powell's comments in focus.

Investors Business Daily

Stock Market Today: Dow Jones, S&P 500 Close Lower; But This Recent IPO Name Bolts Higher For 3rd Straight Day (Live Coverage)

Stock Market Today: Dow Jones, S&P 500 Close Lower; But This Recent IPO Name Bolts Higher For 3rd Straight Day (Live Coverage)

Stocks showed weakness Tuesday with the major indexes closing lower. But a recent IPO name climbed for a third straight day.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

J&J Flexes Its Financial 'Bicep,' Hiking Guidance Despite Tariff Headwinds

Johnson & Johnson stock fell alongside the broader market, despite beating first-quarter calls and hiking its 2025 sales guidance.

Investors Business Daily

J&J Dives After Judge Tosses Out $10 Billion Talc-Based Bankruptcy Plan

Johnson & Johnson stock slumped Tuesday after a judge rejected its $10 billion proposal to settle thousands of talc-tied lawsuits.

3 Dividend Stocks to Buy for a Safe Haven in This Volatile Market

The consistency in their dividend payments makes them dependable stocks in a volatile market.

Investors Business Daily

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out

Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Johnson & Johnson begins battle over baby powder’s ‘link to cancer’ in $10 billion case

Courts have rejected J&J’s two previous efforts to resolve the talc litigation

Slush Puppie’s Parent Hits 52-Week Low. Time to Buy?

J&J Snack Foods, the maker of food and beverage brands such as Slush Puppie, SuperPretzel, and Hola Churros, hit a 52-week low on Tuesday, its 14th in the past 12 months. Here’s why it’s time to buy.

The Guardian - UK

Thousands to sue Johnson & Johnson in UK over alleged talc link to cancer

Group action with 3,500 claimants alleges company knew its talcum powder products contained dangerous asbestos

2 Dividend Kings You Should Snap Up Immediately

Recent earnings from these dividend-paying companies reflects their stability.

How tech leaders are rethinking their cloud strategies in the face of fast-rising costs

As spending on cloud computing rises sharply amid the generative AI boom, executives are on the hunt for cost savings.

Investors Business Daily

J&J Skids After Dow Giant Beat Earnings Views, But 'Prudent' Guidance Disappoints

Johnson & Johnson stock gapped down Wednesday after the health care giant issued light 2025 sales guidance, taking a hit from exchange rates.

The Independent UK

J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by purchasing Intra-Cellular Therapies

People

133,555 stories

Mark Zuckerberg

Christopher Lopez

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

294,933 stories

119,083 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play